To the Editor: The human immunodeficiency virus type 1 (HIV-1) integrase inhibitor dolutegravir is recommended in treatment guidelines as first-line therapy for HIV-1 infection and is characterized by high antiviral potency and a high genetic barrier to the emergence of resistance. Few cases of…